Citations (56)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Batoul Y. Abdallah, Steven D. Horne, Markku Kurkinen, Joshua B. Stevens, Guo Liu, Christine J. Ye, Justin Barbat, Steven W. Bremer & Henry H.Q. Heng. (2014) Ovarian cancer evolution through stochastic genome alterations: defining the genomic role in ovarian cancer. Systems Biology in Reproductive Medicine 60:1, pages 2-13.
Read now
Read now
Giuseppe Bronte, Giuseppe Cicero, Giovanni Sortino, Gianfranco Pernice, Maria Teresa Catarella, Paolo D'Alia, Stefania Cusenza, Silvia Lo Dico, Enrico Bronte, Delia Sprini, Massimo Midiri, Alberto Firenze, Eugenio Fiorentino, Viviana Bazan, Christian Rolfo & Antonio Russo. (2014) Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?. Expert Opinion on Biological Therapy 14:1, pages 103-114.
Read now
Read now
Ju-Han Lee, Xianglan Zhang, Bong Kyung Shin, Eung Seok Lee & Insun Kim. (2009) Mac-2 binding protein and galectin-3 expression in mucinous tumours of the ovary: an annealing control primer system and immunohistochemical study. Pathology 41:3, pages 229-233.
Read now
Read now
Articles from other publishers (53)
Pavel Dundr, Nikola Hájková, Michaela Kendall Bártů, David Cibula, Jana Drozenová, Pavel Fabian, Oluwole Fadare, Filip Frühauf, Jitka Hausnerová, Jan Hojný, Jan Laco, Sigurd F. Lax, Radoslav Matěj, Gábor Méhes, Romana Michálková, Kristýna Němejcová, Naveena Singh, Simona Stolnicu, Marián Švajdler, Tomáš Zima, W. Glenn McCluggage & Ivana Stružinská. (2023) Refined criteria for p53 expression in ovarian mucinous tumours are highly concordant with TP53 mutation status, but p53 expression/TP53 status lack prognostic significance. Pathology.
Crossref
Crossref
Pavel Dundr, Michaela Bártů, Tjalling Bosse, Quang Hiep Bui, David Cibula, Jana Drozenová, Pavel Fabian, Oluwole Fadare, Jitka Hausnerová, Jan Hojný, Nikola Hájková, Radek Jakša, Jan Laco, Sigurd F. Lax, Radoslav Matěj, Gábor Méhes, Romana Michálková, Adam Šafanda, Kristýna Němejcová, Naveena Singh, Simona Stolnicu, Marián Švajdler, Tomáš Zima, Ivana Stružinská & W. Glenn McCluggage. (2023) Primary Mucinous Tumors of the Ovary: An Interobserver Reproducibility and Detailed Molecular Study Reveals Significant Overlap Between Diagnostic Categories. Modern Pathology 36:1, pages 100040.
Crossref
Crossref
Sarah H. Kim, Roisin E. O’Cearbhaill, Preetha Ramalingam & Jennifer J. Mueller. 2023. Diagnosis and Treatment of Rare Gynecologic Cancers. Diagnosis and Treatment of Rare Gynecologic Cancers
77
93
.
Xinxin Zou, Hao Huang, Qingyu Zhang, Zhen Ma, Yumei Chen, Weifeng Wu & Aizhen Fu. (2021) Mucinous Ovarian Tumors With Anaplastic Mural Nodules: Case Report. Frontiers in Medicine 8.
Crossref
Crossref
Tadahiro Shoji, Shunsuke Tatsuki, Marina Abe, Hidetoshi Tomabechi, Eriko Takatori, Yoshitaka Kaido, Takayuki Nagasawa, Masahiro Kagabu, Tsukasa Baba & Hiroaki Itamochi. (2021) Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas. Cancers 13:23, pages 6120.
Crossref
Crossref
S. M. Potapov, D. I. Galata & O. M. Pliten. (2020) Immunohistochemical Characteristics of Proliferative and Apoptotic Processes in Testicular Embryonal Carcinoma. Ukraïnsʹkij žurnal medicini, bìologìï ta sportu 5:1, pages 72-78.
Crossref
Crossref
Abdelazeem Ali Khalaf, Shaymaa Hussein, Adel Fathy Tohamy, Sherif Marouf, Hanan Dawood Yassa, Amr Reda Zaki & Anupam Bishayee. (2019) Protective effect of Echinacea purpurea (Immulant) against cisplatin-induced immunotoxicity in rats. DARU Journal of Pharmaceutical Sciences 27:1, pages 233-241.
Crossref
Crossref
Philippe MoriceSebastien GouyAlexandra Leary. (2019) Mucinous Ovarian Carcinoma. New England Journal of Medicine 380:13, pages 1256-1266.
Crossref
Crossref
Francesca Ricci, Roberta Affatato, Laura Carrassa & Giovanna Damia. (2018) Recent Insights into Mucinous Ovarian Carcinoma. International Journal of Molecular Sciences 19:6, pages 1569.
Crossref
Crossref
Brooke E. Howitt, Kenneth R. Lee, Michael G. Muto, Marisa R. Nucci & Christopher P. Crum. 2018. Diagnostic Gynecologic and Obstetric Pathology. Diagnostic Gynecologic and Obstetric Pathology
865
948
.
Erika Roddy & Jocelyn Chapman. (2017) Genomic insights in gynecologic cancer. Current Problems in Cancer 41:1, pages 8-36.
Crossref
Crossref
Wen Xu, Jack Rush, Kirsty Rickett & Jermaine I.G. Coward. (2016) Mucinous ovarian cancer: A therapeutic review. Critical Reviews in Oncology/Hematology 102, pages 26-36.
Crossref
Crossref
. (2015) Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics 47:8, pages 888-897.
Crossref
Crossref
Reinou S. Groen, David M. Gershenson & Amanda Nickles Fader. (2015) Updates and emerging therapies for rare epithelial ovarian cancers: One size no longer fits all. Gynecologic Oncology 136:2, pages 373-383.
Crossref
Crossref
Álvaro Henrique Ingles Garces, Mariane Sousa Fontes Dias, Eduardo Paulino, Carlos Gil Moreira Ferreira & Andréia Cristina de Melo. (2014) Treatment of ovarian cancer beyond chemotherapy: Are we hitting the target?. Cancer Chemotherapy and Pharmacology 75:2, pages 221-234.
Crossref
Crossref
Marcela G. del Carmen. 2014. Uncommon Gynecologic Cancers. Uncommon Gynecologic Cancers
64
69
.
K. Muyldermans, Ph. Moerman, F. Amant, K. Leunen, P. Neven & I. Vergote. (2013) Primary invasive mucinous ovarian carcinoma of the intestinal type: Importance of the expansile versus infiltrative type in predicting recurrence and lymph node metastases. European Journal of Cancer 49:7, pages 1600-1608.
Crossref
Crossref
Georgina L Ryland, Sally M Hunter, Maria A Doyle, Simone M Rowley, Michael Christie, Prue E Allan, David DL Bowtell, Kylie L Gorringe & Ian G Campbell. (2013)
RNF43
is a tumour suppressor gene mutated in mucinous tumours of the ovary
. The Journal of Pathology 229:3, pages 469-476.
Crossref
Crossref
Jay D Naik, Jenny Seligmann & Timothy J Perren. (2012) Mucinous tumours of the ovary. Journal of Clinical Pathology 65:7, pages 580-584.
Crossref
Crossref
Ignacio Romero & Robert C. BastJr.Jr.. (2012) Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy. Endocrinology 153:4, pages 1593-1602.
Crossref
Crossref
Linda E Kelemen & Martin Köbel. (2011) Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. The Lancet Oncology 12:11, pages 1071-1080.
Crossref
Crossref
Janneta Tcherkassova, Carolina Abramovich, Rafael Moro, Chen Chen, Ralph Schmit, Angela Gerber & Ricardo Moro. (2011) Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer. Tumor Biology 32:4, pages 831-838.
Crossref
Crossref
Ketao Jin, Kuifeng He, Fei Teng, Na Han, Guangliang Li, Zhenzhen Xu & Lisong Teng. (2011) Heterogeneity in primary tumors and corresponding metastases: could it provide us with any hints to personalize cancer therapy?. Personalized Medicine 8:2, pages 175-182.
Crossref
Crossref
Martin Köbel & David Huntsman. (2011) Molecular Pathology of Ovarian Carcinomas. Surgical Pathology Clinics 4:1, pages 275-296.
Crossref
Crossref
Marisa R. Nucci, Christopher P. Crum & Kenneth R. Lee. 2011. Diagnostic Gynecologic and Obstetric Pathology. Diagnostic Gynecologic and Obstetric Pathology
818
895
.
Jason Madore, Fengge Ren, Ali Filali‐Mouhim, Lilia Sanchez, Martin Köbel, Patricia N Tonin, David Huntsman, Diane M Provencher & Anne‐Marie Mes‐Masson. (2009) Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. The Journal of Pathology 220:3, pages 392-400.
Crossref
Crossref
Nikos G. Gavalas, Alexandra Karadimou, Meletios A. Dimopoulos & Aristotelis Bamias. (2010) Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy: Potential for Treatment Utilization. Clinical and Developmental Immunology 2010, pages 1-15.
Crossref
Crossref
Nikos G. Gavalas, Meletios A. Dimopoulos & Aristotelis Bamias. (2009) Anti-tumor immune response in ovarian cancer: clinical implications, prognostic significance and potential for novel treatment strategies. Oncology Reviews 3:3, pages 173-186.
Crossref
Crossref
Cheryl L. Robbins, Maura K. Whiteman, Susan D. Hillis, Kathryn M. Curtis, Jill A. McDonald, Phyllis A. Wingo, Aniket Kulkarni & Polly A. Marchbanks. (2009) Influence of Reproductive Factors on Mortality after Epithelial Ovarian Cancer Diagnosis. Cancer Epidemiology, Biomarkers & Prevention 18:7, pages 2035-2041.
Crossref
Crossref
P de Graeff, A P G Crijns, S de Jong, M Boezen, W J Post, E G E de Vries, A G J van der Zee & G H de Bock. (2009) Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. British Journal of Cancer 101:1, pages 149-159.
Crossref
Crossref
HanByoul Cho & Jae-Hoon Kim. (2009) Lipocalin 2 Expressions Correlate Significantly With Tumor Differentiation in Epithelial Ovarian Cancer. Journal of Histochemistry & Cytochemistry 57:5, pages 513-521.
Crossref
Crossref
Michael L. Cibull & Rouzan G. Karabakhtsian. (2008) Editorial. Cancer 112:10, pages 2108-2111.
Crossref
Crossref
M.L. HARRISON, C. JAMESON & M.E. GORE. (2008) Mucinous ovarian cancer. International Journal of Gynecological Cancer 18:2, pages 209-214.
Crossref
Crossref
Irene Visintin, Ziding Feng, Gary Longton, David C. Ward, Ayesha B. Alvero, Yinglei Lai, Jeannette Tenthorey, Aliza Leiser, Ruben Flores-Saaib, Herbert Yu, Masoud Azori, Thomas Rutherford, Peter E. Schwartz & Gil Mor. (2008) Diagnostic Markers for Early Detection of Ovarian Cancer. Clinical Cancer Research 14:4, pages 1065-1072.
Crossref
Crossref
Michelle L. Harrison, Thomas Ind, Peter Blake & Martin E. Gore. 2005. The Cancer Handbook. The Cancer Handbook.
Dimitrios Pectasides, Eirini Pectasides, Amanda Psyrri & Theofanis Economopoulos. (2006) Treatment Issues in Clear Cell Carcinoma of the Ovary: A Different Entity?. The Oncologist 11:10, pages 1089-1094.
Crossref
Crossref
Dimitrios Pectasides, George Fountzilas, Gerassimos Aravantinos, Charalambos Kalofonos, Helen Efstathiou, Dimitrios Farmakis, Dimosthenes Skarlos, Nikolaos Pavlidis, Theofanis Economopoulos & Meletios A. Dimopoulos. (2006) Advanced stage clear-cell epithelial ovarian cancer: The Hellenic cooperative oncology group experience. Gynecologic Oncology 102:2, pages 285-291.
Crossref
Crossref
Fred W. Wamunyokoli, Tomas Bonome, Ji-Young Lee, Colleen M. Feltmate, William R. Welch, Mike Radonovich, Cindy Pise-Masison, John Brady, Ke Hao, Ross S. Berkowitz, Samuel Mok & Michael J. Birrer. (2006) Expression Profiling of Mucinous Tumors of the Ovary Identifies Genes of Clinicopathologic Importance. Clinical Cancer Research 12:3, pages 690-700.
Crossref
Crossref
Takayuki Amikura, Masayuki Sekine, Yasuo Hirai, Seiichiro Fujimoto, Masayuki Hatae, Iwao Kobayashi, Tsuneo Fujii, Ichiro Nagata, Kimio Ushijima, Koshiro Obata, Mitsuaki Suzuki, Mitsuhiro Yoshinaga, Naohiko Umesaki, Shinji Satoh, Takayuki Enomoto, Satoru Motoyama, Koji Nishino, Kazufumi Haino & Kenichi Tanaka. (2006) Mutational analysis of TP53 and p21 in familial and sporadic ovarian cancer in Japan. Gynecologic Oncology 100:2, pages 365-371.
Crossref
Crossref
Bojana Petrovic, Milica Perovic, Ivana Novakovic, Jasmina Atanackovic, Branka Popovic, Ljiljana Lukovic & Spasoje Petkovic. (2006) Analysis of loss of heterozygosity of the tumor suppressor genes p53 and BRCA1 in ovarial carcinomas. Vojnosanitetski pregled 63:9, pages 813-818.
Crossref
Crossref
Tiina-Liisa Erkinheimo, Anna Sivula, Heini Lassus, Mira Heinonen, Henry Furneaux, Caj Haglund, Ralf Butzow & Ari Ristim?ki. (2005) Cytoplasmic HuR expression correlates with epithelial cancer cell but not with stromal cell cyclooxygenase-2 expression in mucinous ovarian carcinoma. Gynecologic Oncology 99:1, pages 14-19.
Crossref
Crossref
Dimitrios Pectasides, George Fountzilas, Gerasimos Aravantinos, Haralampos P. Kalofonos, Eleni Efstathiou, Emmanouel Salamalekis, Dimitrios Farmakis, Dimosthenis Skarlos, Evangelos Briasoulis, Theofanis Economopoulos & Meletios A. Dimopoulos. (2005) Advanced stage mucinous epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience. Gynecologic Oncology 97:2, pages 436-441.
Crossref
Crossref
Allison W. Kurian, Raymond R. Balise, Valerie McGuire & Alice S. Whittemore. (2005) Histologic types of epithelial ovarian cancer: have they different risk factors?. Gynecologic Oncology 96:2, pages 520-530.
Crossref
Crossref
IMgan F Huang, Mala Gupta & Sunny Luke. 2005. Molecular Genetics, Gastrointestinal Carcinoma, and Ovarian Carcinoma. Molecular Genetics, Gastrointestinal Carcinoma, and Ovarian Carcinoma
307
332
.
M.A. Hayat. 2005. Molecular Genetics, Gastrointestinal Carcinoma, and Ovarian Carcinoma. Molecular Genetics, Gastrointestinal Carcinoma, and Ovarian Carcinoma
287
306
.
J. S. Nielsen, E. Jakobsen, B. HOlund, K. Bertelsen & A. Jakobsen. (2004) Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. International Journal of Gynecological Cancer 14:6, pages 1086-1096.
Crossref
Crossref
Daniel G Rosen, Xuelin Huang, Michael T Deavers, Anais Malpica, Elvio G Silva & Jinsong Liu. (2004) Validation of tissue microarray technology in ovarian carcinoma. Modern Pathology 17:7, pages 790-797.
Crossref
Crossref
Estrid V. S. Høgdall, Andy Ryan, Susanne K. Kjaer, Jan Blaakaer, Lise Christensen, Johannes E. Bock, Eva Glud, Ian J. Jacobs & Claus K. Høgdall. (2004) Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma. Cancer 100:11, pages 2387-2395.
Crossref
Crossref
Russell HoggMichael Friedlander. (2004) Biology of Epithelial Ovarian Cancer: Implications for Screening Women at High Genetic Risk. Journal of Clinical Oncology 22:7, pages 1315-1327.
Crossref
Crossref
Viviane HessRoger A'HernNazar NasiriD. Michael KingPeter R. BlakeDesmond P.J. BartonJohn H. ShepherdT. IndJ. BridgesK. HarringtonStanley B. KayeMartin E. Gore. (2004) Mucinous Epithelial Ovarian Cancer: A Separate Entity Requiring Specific Treatment. Journal of Clinical Oncology 22:6, pages 1040-1044.
Crossref
Crossref
Sang Soo Seo, Yong Sang Song, Dae-hee Kang, In Ae Park, Yung Jue Bang, Soon Beom Kang & Hyo Pyo Lee. (2004) Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. Gynecologic Oncology 92:3, pages 927-935.
Crossref
Crossref
. (2003) P53 codon 72 polymorphism and BRCA 1 and 2 mutations in ovarian epithelial malignancies in black South Africans. International Journal of Gynecological Cancer 13:4, pages 444-449.
Crossref
Crossref
N. Pisal, M. Sindos & A. Singer. (2003) Re: Assessment of Plasma DNA Levels, Allelic Imbalance, and CA 125 as Diagnostic Tests for Cancer. JNCI Journal of the National Cancer Institute 95:4, pages 331-331.
Crossref
Crossref